RT Journal Article
SR Electronic
T1 Review of clinical characteristics and laboratory findings of COVID-19 in children-Systematic review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.23.20200410
DO 10.1101/2020.09.23.20200410
A1 Kharoud, Harmeet Kaur
A1 Asim, Rizwana
A1 Siegel, Lianne
A1 Chahal, Lovepreet
A1 Singh, Gagan Deep
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.23.20200410.abstract
AB OBJECTIVE To conduct a systematic review and meta-analysis to assess the prevalence of various clinical symptoms and laboratory findings of COVID-19 in children.METHODS PubMed, MEDLINE, and SCOPUS databases were searched to include studies conducted between January 1, 2020, and July 15, 2020 which reported data about clinical characteristics and laboratory findings in laboratory-confirmed diagnosis of COVID-19 in pediatric patients. Random effects meta-analysis using generalized linear mixed models was used to estimate the pooled prevalence.RESULTS The most prevalent symptom of COVID-19 in children was 46.17% (95%CI 39.18-53.33%), followed by cough (40.15%, 95%CI 34.56-46.02%). Less common symptoms were found to be dyspnea, vomiting, nasal congestion/rhinorrhea, diarrhea, sore throat/pharyngeal congestion, headache, and fatigue. The prevalence of asymptomatic children was 17.19% (95%CI 11.02-25.82%).The most prevalent laboratory findings in COVID-19 children were elevated Creatinine Kinase (26.86%, 95%CI 16.15-41.19%) and neutropenia (25.76%, 95%CI 13.96-42.58%). These were followed by elevated LDH, thrombocytosis, lymphocytosis, neutrophilia, elevated D Dimer, Elevated CRP, elevated ESR, leukocytosis, elevated AST and leukopenia. There was a low prevalence of elevated ALT and lymphopenia in children with COVID-19.CONCLUSIONS AND RELEVANCE This study provides estimates of the pooled prevalence of various symptoms and laboratory findings of COVID-19 in the pediatric population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding sources- NIH NHLBI T32HL129956 (LS)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Since this is a meta-analysis IRB approval was not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudies referred to in the manuscript are available freely in pubmed.